RLMD
Relmada Therapeutics Inc.
$7.17
+$0.13(+1.85%)
50
Overall
60
Value
63
Tech
28
Quality
Market Cap
$50.78M
Volume
726.37K
52W Range
$0.36 - $8.00
Target Price
$12.80
Order:
Income Statement
| Metric | Trend | Chart | 2016 Jun | 2017 Jun | 2018 Jun | 2019 Jun | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $130.3K | $211.0K | $2.4K | -- | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $130.3K | $211.0K | $2.4K | -- | -- | -- | -- | -- | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-16.6K | $-16.6K | $-16.6K | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $130.3K | $211.0K | $2.4K | -- | -- | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-16.2M | $-7.2M | $-6.9M | $12.7M | $60.8M | $125.7M | $161.2M | $103.7M | $83.9M | $59.1M | ||
| Research & Development | $6.2M | $1.3M | $2.9M | $7.0M | $36.0M | $90.6M | $113.3M | $54.8M | $46.2M | $26.9M | ||
| Research Expense | $6.2M | $1.3M | $2.9M | $7.0M | $36.0M | $90.6M | $113.3M | $54.8M | $46.2M | $26.9M | ||
| Selling, General & Administrative | $10.0M | $5.9M | $4.0M | $5.7M | $24.9M | $35.1M | $47.9M | $48.9M | $37.7M | $32.2M | ||
| General & Administrative Expenses | $10.0M | $5.9M | $4.0M | $5.7M | $24.9M | $35.1M | $47.9M | $48.9M | $37.7M | $32.2M | ||
| Salaries & Wages | $-1.2M | $-704.5K | $-518.0K | $-1.2M | $90.7K | $112.9K | -- | $43.8M | -- | $14.8M | ||
| Depreciation & Amortization | -- | -- | -- | -- | $3.8K | $1.3K | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | -- | $3.8K | $1.3K | -- | -- | -- | -- | ||
| Amortization | -- | -- | $-6.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | $8.7K | $6.5K | -- | $283.6K | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-16.1M | $-7.0M | $-6.9M | $-12.7M | $-60.8M | $-125.7M | $-161.2M | $-103.7M | $-83.9M | $-59.1M | ||
| EBITDA | $-2.9M | $-6.2M | $-7.9M | $-15.9M | $-60.9M | $-125.7M | $-161.2M | $-98.8M | $-80.0M | $-57.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $761.0K | $-1.4M | $-1.2M | $-2.7M | $-5.2M | -- | -- | ||
| Intinc | -- | $5.2K | -- | -- | -- | -- | $6.4M | $5.2M | $3.5M | $1.4M | ||
| Net Non-Operating Interest Income/Expense | -- | $721.8K | $-708.9K | $-761.0K | $1.4M | $1.2M | $2.7M | $5.2M | $3.5M | $1.4M | ||
| Gain on Sale of Securities | -- | $100.0K | -- | $-54.6K | $-16.9K | $-1.2M | $-4.8M | $-241.2K | $381.7K | $319.0K | ||
| Other Income/Expense | $-13.1M | $-721.8K | $-2.4K | $3.8M | $16.9K | $1.2M | $1.5M | $241.2K | $-381.7K | $-319.0K | ||
| Other Special Charges | $130.3K | $5.2K | $2.4K | $-3.8M | $14.9K | $4.0K | $6.4M | $397.0K | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | $-54.6K | $1.8M | -- | $6.4M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-3.0M | $-6.3M | $-9.0M | $-16.6M | $-60.9M | $-125.7M | $-161.2M | $-98.8M | $-80.0M | $-57.4M | ||
| Pre-Tax Income | $-3.0M | $-6.3M | $-9.0M | $-17.3M | $-59.5M | $-125.8M | $-157.0M | $-98.8M | $-80.0M | $-57.4M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | $6.2M | $88.6M | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-3.0M | $-6.3M | $-9.0M | $-17.3M | $-59.5M | $-125.8M | $-157.0M | $-98.8M | $-80.0M | $-57.4M | ||
| Net Income (Continuing Operations) | $-3.0M | $-6.3M | $-9.0M | $-17.3M | $-59.5M | $-125.8M | $-157.0M | $-98.8M | $-80.0M | $-57.4M | ||
| Net Income (Discontinued Operations) | $-3.0M | $-6.3M | $-9.0M | $-17.3M | $-59.5M | $-125.8M | $-157.0M | $-98.8M | $-80.0M | $-57.4M | ||
| Net Income (Common Stockholders) | $-3.0M | $-6.3M | $-9.0M | $-17.3M | $-59.5M | $-125.8M | $-157.0M | $-98.8M | $-80.0M | $-57.4M | ||
| Normalized Income | -- | $-4.1M | $-7.1M | -- | $-48.8M | $-99.3M | -- | -- | -- | $-56.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $16.2M | $-7.2M | $-6.9M | $12.7M | $60.8M | $125.7M | $161.2M | $103.7M | $83.9M | $59.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $2.9M | $3.0M | $3.1M | $6.3M | $15.6M | $17.6M | $29.6M | $30.1M | $30.2M | $39.5M | ||
| Average Shares Outstanding (Diluted) | $2.9M | $3.0M | $3.2M | $6.3M | $15.6M | -- | $29.6M | $30.1M | $30.2M | $39.5M | ||
| Shares Outstanding | $3.0M | $3.1M | $3.1M | $9.9M | $16.7M | $29.4M | $30.1M | $104.9M | $104.9M | $104.9M | ||
| Basic EPS | -- | -- | -- | -- | $-3.81 | $-7.16 | $-5.3 | $-3.28 | $-2.65 | $-1.45 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-3.81 | $-7.16 | $-5.3 | $-3.28 | $-2.65 | $-1.45 | ||
| Diluted EPS | $-1.04 | $-2.08 | $-2.84 | $-2.76 | $-3.81 | $-7.16 | $-5.3 | $-3.28 | $-2.65 | $-1.45 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-2.76 | -- | -- | $-5.3 | $-3.28 | $-2.65 | $-1.45 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D | -- | -- | -- | $-54.6K | -- | -- | -- | -- | -- | -- | ||
| Acquired In Process Rn D Income | $13.1M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | $59.4K | -- | -- | -- | -- | -- | -- | ||
| Net Operating Interest Income Expense | $1.7K | $-550 | $-1.3M | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | $-1.1M | -- | -- | $-6.4M | -- | -- | -- | ||
| Other Gand A | $10.0M | $5.9M | $4.0M | $5.7M | $24.9M | $35.1M | $47.9M | $48.9M | $37.7M | $32.2M | ||
| Realized Capital Gain | $13.1M | $716.6K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $10.0M | $5.9M | $4.0M | $-114.8K | -- | -- | $-9.0K | $-7.0K | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $-1.8M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLMD | $7.17 | +1.8% | 726.37K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Relmada Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW